

## Sponsored Research

## Switzerland | Financial Services Holdings

### Analysér

15 May 2025

#### Company Profile

#### Corporate Events

#### Buy

Recommendation unchanged

Share price: CHF 168.40

closing price as of 14/05/2025

Target price: CHF 231.00

Target Price unchanged

Upside/Downside Potential 37.2%

Reuters/Bloomberg

HBMN.S/HBMN.SW

Market capitalisation (CHFm) 1,157

Current N° of shares (m) 7

Free float 80%

Daily avg. no. trad. sh. 12 mth (k) 6

Daily avg. trad. vol. 12 mth (k) 519.74

Price high/low 12 months 213.50 / 164.00

Abs Perfs 1/3/12 mths (%) -2.55/-10.43/-14.95

#### Estimated NAV breakdown (CHFm)


Total Net Asset Value 0.0 0%

NAVPS (EUR) nm

Share price\*: CHF 168.40

#### Shareholders

Nogra Group (Giuliani Family) 16%; Carnegie Fonder AB 1.06%; Autocontr?le 3%;



Source: FactSet

— HBM HEALTHCARE INVESTMENTS — SMI (Rebased)

#### Analyst(s)

Arnaud Cadart

arnaud.cadart@cic.fr

+33 1 53 48 80 84

## Progress in 2025 overshadowed by the weak USD

**The facts:** HBM Healthcare Investments (HBM HI) published its financial report this morning for the 2025 fiscal year ended March 31, with net income confirmed at CHF19m.

**Our analysis:** Attrib. net profit of CHF19m (EPS of CHF2.72) reflects a loss of CHF47m in Q4 due to the decline in the value of the listed portfolio and currency depreciation, primarily of the \$ against the CHF. NAV per share stood at CHF244.4 as of March 31, up 1.5% y-o-y. The annual profit does not accurately reflect the strong progress made in the portfolio: 1) HBM HI benefitted from a revaluation of its unlisted assets at CHF114m, thanks to its exposure to Yellow Therapeutics, sold to J&J in the summer, the continued development of Swixx and six IPOs. That of Sai Life Sciences in Mumbai enabled it to place 60% of its position and highlight high returns on invested capital: 12.1x in INR and 8.5x in CHF on the portion realized. HBM HI also benefitted from its 9% stake in Dren Bio, which sold DR-0201, a bispecific antibody targeting myeloid cells (white blood cells that circulate in the blood and tissues) to Sanofi. This antibody is effective in reducing excess B lymphocytes in patients with autoimmune diseases. The transaction contributes \$50m to HBM HI. The portfolio of unlisted direct lines represents 35% of NAV as of March 31; 2) The listed portfolio (49% of the same NAV, including 26% via IPOs co-managed by HBM HI) saw its net valuation decline by CHF64m (-3.6%); 3) The valuation of fund holdings declined slightly (-CHF5m) and they now account for 10% of gross assets; 4) Net cash amounted to CHF66m at the end of the period (before the recovery of Dren Bio) and the dividend was announced as stable at CHF7.5 per share, representing a yield of nearly 4.5% on the last quoted price; 5) The group is confident in the quality and strength of its portfolio to weather a turbulent environment that is encouraging consolidation, particularly in biotechnology.

**Conclusion & Action:** The group has once again demonstrated its ability to identify, develop, and enhance the value of high-quality companies around the world. The outlook for Swixx's valuation in early 2026 is also positive. We find the momentum and 30% discount to NAV particularly attractive. Buy rating and target price of CHF231 confirmed.